Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -41,4 M
Net income 2017 -35,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,47 M
EBIT 2018 -43,1 M
Net income 2018 -43,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 1,70x
Capitalization 14,4 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.It... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
08/14 Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura w..
08/10 ANTHERA PHARMACEUTICALS : Findings from Anthera Pharmaceuticals Inc Update Under..
08/10 ANTHERA PHARMACEUTICALS : Announces FDA Orphan Drug Designation for Blisibimod f..
08/09 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Financial Statements a..
08/09 ANTHERA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
08/09 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Results of Operations ..
08/09 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
08/09 ANTHERA PHARMACEUTICALS : Announces FDA Orphan Drug Designation for Blisibimod f..
08/09 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
08/09 ANTHERA PHARMACEUTICALS : beats 2Q profit forecasts
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 4
Average target price 6,75 $
Spread / Average Target 411%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
William R. Shanahan Chief Medical Officer
David E. Thompson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR14
AMGEN14.42%122 702
CELGENE CORPORATION10.09%99 695
GILEAD SCIENCES0.70%94 810
REGENERON PHARMACEUTICALS27.48%50 334
VERTEX PHARMACEUTICALS102.27%37 568